Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Neuronetics Inc
(NQ:
STIM
)
0.9650
-0.0093 (-0.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neuronetics Inc
< Previous
1
2
3
4
5
6
Next >
NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month
May 02, 2023
Campaign features patients’ experiences to support others with depression
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
May 01, 2023
Strategic role strengthens NeuroStar® Advanced Therapy commercialization team
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Expanded TMS Access through United HealthCare
April 28, 2023
UHC Medicare Advantage plans in NGS states expand access via NPPs
From
Neuronetics
Via
GlobeNewswire
Neuronetics's Return On Capital Employed Overview
March 09, 2023
Via
Benzinga
Preview: Neuronetics's Earnings
March 06, 2023
Via
Benzinga
Neuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMS
January 19, 2023
Via
Benzinga
Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy
April 13, 2023
BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMS
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities
April 06, 2023
Fifth FDA clearance in less than two years offers greater connectivity and flexibility to improve the patient and provider experience
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
March 16, 2023
Award recognizes NeuroStar for its significant contributions toward patient wellbeing
From
Neuronetics
Via
GlobeNewswire
Neuronetics's Return On Capital Employed Overview
December 06, 2022
Via
Benzinga
Short Volatility Alert: Neuronetics, Inc.
October 21, 2022
On Thursday, shares of Neuronetics, Inc. (NASDAQ: STIM) experienced volatile short activity. After the activity, the stock price went down -1.74% to $2.83. The overall sentiment for STIM has been...
Via
Benzinga
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
March 11, 2023
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...
Via
Benzinga
Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives
March 02, 2023
United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients
From
Neuronetics
Via
GlobeNewswire
Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
February 23, 2023
Company Launches a New Educational Campaign For Providers
From
Neuronetics
Via
GlobeNewswire
Short Volatility Alert: Neuronetics, Inc.
September 23, 2022
On Thursday, shares of Neuronetics, Inc. (NASDAQ: STIM) experienced volatile short activity. After the activity, the stock price went up +0.76% to $2.65. The overall sentiment for STIM has been...
Via
Benzinga
Neuronetics Sponsors the 5th International Brain Stimulation Conference
February 21, 2023
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer
February 16, 2023
New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners
February 10, 2023
NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
January 17, 2023
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety
From
Neuronetics
Via
GlobeNewswire
Neuronetics Settles Unfair Competition Related Litigation Against BrainsWay
January 10, 2023
Via
Benzinga
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
December 05, 2022
NeuroStar’s technology once again recognized as an effective non-drug treatment for patients
From
Neuronetics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
December 02, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 17, 2022
Via
Benzinga
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
November 14, 2022
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
October 31, 2022
NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health
From
Neuronetics
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
October 25, 2022
Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS
From
Neuronetics
Via
GlobeNewswire
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
September 29, 2022
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...
Via
Benzinga
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
September 28, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 27, 2022
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.